TEZZURA Trademark

Trademark Overview


On Wednesday, August 16, 2017, a trademark application was filed for TEZZURA with the United States Patent and Trademark Office. The USPTO has given the TEZZURA trademark a serial number of 87571128. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 6, 2021. This trademark is owned by Allergan Sales, LLC. The TEZZURA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations...
tezzura

General Information


Serial Number87571128
Word MarkTEZZURA
Filing DateWednesday, August 16, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 6, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 5, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceuticals and medicines for the central nervous system; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 22, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Monday, December 6, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 6, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, April 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 2, 2021EXTENSION 4 GRANTED
Friday, April 2, 2021EXTENSION 4 FILED
Friday, April 2, 2021TEAS EXTENSION RECEIVED
Thursday, October 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 20, 2020EXTENSION 3 GRANTED
Tuesday, October 20, 2020EXTENSION 3 FILED
Tuesday, October 20, 2020TEAS EXTENSION RECEIVED
Tuesday, March 31, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 27, 2020EXTENSION 2 GRANTED
Friday, March 27, 2020EXTENSION 2 FILED
Friday, March 27, 2020TEAS EXTENSION RECEIVED
Thursday, September 26, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 24, 2019EXTENSION 1 GRANTED
Tuesday, September 24, 2019EXTENSION 1 FILED
Tuesday, September 24, 2019TEAS EXTENSION RECEIVED
Tuesday, April 30, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 5, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 5, 2019PUBLISHED FOR OPPOSITION
Wednesday, February 13, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 31, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 5, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 5, 2018NON-FINAL ACTION E-MAILED
Thursday, July 5, 2018NON-FINAL ACTION WRITTEN
Wednesday, June 6, 2018SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Tuesday, June 5, 2018ASSIGNED TO LIE
Tuesday, November 21, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, November 21, 2017LETTER OF SUSPENSION E-MAILED
Tuesday, November 21, 2017SUSPENSION LETTER WRITTEN
Monday, November 20, 2017ASSIGNED TO EXAMINER
Tuesday, August 22, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, August 21, 2017NEW APPLICATION ENTERED IN TRAM